Dermira, Inc.

Neurmedix, Inc.

Gilead Sciences, Inc.

Cymabay Therapeutics, Inc.

Journey Medical Corporation

Artelo Biosciences, Inc.

Takeda Pharmaceutical Company Limited

Achillion Pharmaceuticals, Inc.

Laurus Labs Private Limited

Metabolex, Inc.

Harbor Therapeutics, Inc.

Aptuit (west Lafayette), LLC

Mark Andres

Patricia Andres

Igor Ivanisevic

Jennifer Leigh Nelson

Anthony Adrian Shaw

Delphine Caroline Imbert

Lisa Lynn McQueen

Stephan Xander Mattheus Boerrigter

Jon Gordon Selbo

John Allan Statler

Kyle Stephens

Steven K White

Brenton Skylar Wolfe

Charles A McWherter

Jiangao Song

Ekaterina Albert

Fang Ma

Gregory Notte

R Martin Emanuele

Ernest A Carra

Valeriya N Smolenskaya

Olga Viktorovna Lapina

Anna Chiu

Stephen Paul Lathrop

Tanise Shattock-Gordon

Tabitha Williford

Brenda J Burke Chan

Lok Him Yu

Avinash S Phadke

Akihiro Hashimoto

Keith Lorimer

Linda Jane McCausland

Masna Mahesh

Thatipally Suresh

Jan-Olav Henck

Gottumukkala V Subbaraju

Hindupur R Mohan

Charles A Mcwherter

Brenda J Chan

Valeriya Smolenskaya

Brenton Wolf

This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Morphic forms of complement factor D inhibitors

Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4'-dipyridyl are also disclosed herein.

Solid forms of cannabidiol and uses thereof

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

Glycopyrrolate salts

Described herein are solid state 17&#x3b1;-ethynylandrost-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17&#x3b1;-ethynylandrost-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Crystalline solvate forms of a pharmaceutical

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Solid forms of an ASK1 inhibitor

The invention provides and describes solid state 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;, 7&#x3b2;,17&#x3b2;-triol and uses of such formulations in treating the described conditions.

Treatment methods using pharmaceutical solid state forms

The invention provides and describes solid state 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol and uses of such formulations in treating the described conditions.

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide(Compound I) were prepared and characterized in the solid state:  Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline anhydrate forms of a pharmaceutical

Growing community of inventors

West Lafayette, IN, United States of America

Mark Andres